In the USA, a billion-dollar Takeover in the pharmaceutical industry, the sorts at present on several fronts, new,. The volume of Deals is more than 65 billion euros.
The industry giant Bristol-Myers Squibb intends to take over the biopharmaceutical specialists Celgene for the equivalent of approximately 74 billion U.S. dollars (around 65.2 billion euros). The Board of Directors of Celgene have agreed with the business already, so Bristol-Myers on Thursday.
Celgene shareholders will receive for each share, a paper by Bristol-Myers Squibb and 50 dollars, the company said on Thursday in New York. In addition, Celgene shareholders get the right to further success payments.
New giant on the market of Medicines
The giant business. a leading manufacturer of biopharmaceutical drugs, forms, wants to focus on cancer drugs, inflammation and diseases of the immune system and the blood vessels The companies anticipate closing in the third quarter of 2019. The companies aim to achieve by the year 2022, annual savings of $ 2.5 billion. Bristol-Myers intends to carry out after the completion of addition, an accelerated share repurchase of up to five billion dollars.
Sales targets increases and savings attached
The papers of Celgene were on Wednesday at 66,64 dollars from the trade went to, Bristol-Myers shares cost 52 dollars. In the premarket trading, the papers of Bristol, lost 13 percent, Celgene shares rose by more than 30 percent. The shareholders of the biotech company will receive in the framework of the deal is also an option that guarantees you a payment of nine dollars, if three certain new drugs from Celgene be approved in the next few years in the United States.
Together, the two companies hope to be able to in the next time six new drugs with sales potential of more than 15 billion dollars on the market. Through the acquisition of Bristol-Myers also expects annual savings of around $ 2.5 billion by 2022. The completion of the deal, the group is expected in the third quarter.
The industry is in transition
Bristol-Myers can continue to expand with the Acquisition is also be a lucrative business with the cancer immune therapies. Celgene had increased in the area just last year with the purchase of the cancer specialists Juno Therapeutics for nine billion dollars. The pharmaceutical industry is in a constant process of concentration. Since many of the patents expire and the research and development costs rise, bundling more and more companies forces. In the past year, the Japanese drug manufacturer Takeda announced the largest acquisition in the industry. He is responsible for $ 59 billion to the Irish rival Shire.
dk/hb (rtr/dpa)